Sanofi's first quarter earnings edges past estimates ahead of CEO change

Sanofi SA

23/04/2026 06:30

LONDON, April 23 (Reuters) - French drugmaker Sanofi SASY.PA on Thursday reported first-quarter profit and revenue above market expectations, boosted by resilient demand for its blockbuster asthma and eczema drug Dupixent.

The company also reaffirmed its expectations of a high single-digit percentage sales growth at constant currency rates for the year, with business operating income expected to grow slightly faster than sales.

Sanofi's results come months after the sudden ouster of former CEO Paul Hudson in February, as the Briton failed to revive the company's drug pipeline and was hit by a string of disappointing trial updates for alternatives expected to reduce reliance on Dupixent.

New CEO Belén Garijo is set to take the top job at the end of April.

Paris-based Sanofi reported total sales of 10.51 billion euros ($12.29 billion) for the quarter ended March 31, 2026. That compares with the analysts' average estimate of 10.22 billion euros compiled by Vara Research.

Quarterly business operating income was 2.97 billion euros ($3.47 billion), beating average analyst estimates of 2.85 billion euros.

Sales of Dupixent, developed with U.S. partner Regeneron REGN.O, rose 30.8% at constant exchange rates to 4.17 billion euros ($4.88 billion).

Analysts were expecting sales of the drug to be 3.89 billion euros for the first quarter.

($1 = 0.8548 euros)

(Reporting by Bhanvi Satija in London and Mariam Sunny in Bengaluru; Editing by Nivedita Bhattacharjee)

((Bhanvi.Satija@thomsonreuters.com; +44 7920644259;))